Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Sign a Collaboration Agreement to Conduct a Phase 2 Randomized, Clinical Trial in Early-Stage Breast Cancer in Europe for INT230-6, Intensity's Lead Drug Candidate
Intensity Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update [Yahoo! Finance]
Intensity Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
Intensity Therapeutics to Participate in the LD Micro Invitational XIV Conference April 8 - 9, 2024 [Yahoo! Finance]
Intensity Therapeutics to Participate in the LD Micro Invitational XIV Conference April 8 - 9, 2024